Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma

Journal of Surgical Oncology

Volumn 109, Issue 3, 2014, Pages 275-279

  Jeon, Dae Geun ^a   Kong, Chang Bae ^a   Cho, Wan Hyeong ^a   Song, Won Seok ^a   Cho, Sang Hyun ^a   Choi, Sung Woo ^a   Lee, Soo Yong ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

osteosarcoma; prognosis; ROC curve; tumor volume

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE BIOPSY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CUTOFF VALUE; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; HUMERUS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; OSTEOSARCOMA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR VOLUME; YOUNG ADULT;

OSTEOSARCOMA; PROGNOSIS; ROC CURVE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84893665412     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23496     Document Type: Article

References (28)

1. Ozaki T, Flege S, Kevric M, et al.: Osteosarcoma of the pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003; 21: 334-341.
2. Song WS, Kong CB, Jeon DG, et al.: Prognosis of extremity osteosarcoma in patients aged 40-60 years: A cohort/case controlled study at a single institute. Eur J Surg Oncol 2010; 36: 483-488.
3. Bacci G, Longhi A, Versari M, et al.: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154-1161.
4. Kim MS, Lee SY, Cho WH, et al.: Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol 2008; 97: 456-461.
5. Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
6. Davis AM, Bell RS, Goodwin PJ:, Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-431.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. Shin KH, Moon SH, Suh JS, Yang WI:, Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res 2000; 376: 200-208.
9. Song WS, Jeon DG, Kong CB, et al.: Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma. Ann Surg Oncol 2011; 18: 1710-1716.
10. Kong CB, Song WS, Cho WH, et al.: Local recurrence has only a small effect on survival in high-risk extremity osteosarcoma. Clin Orthop Relat Res 2012; 470: 1482-1490.
11. Holscher HC, Bloem JL, Vanel D, et al.: Osteosarcoma: Chemotherapy-induced changes at MR imaging. Radiology 1992; 182: 839-844.
12. Kim MS, Lee SY, Cho WH, et al.: Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci 2009; 14: 292-297.
13. Kim MS, Cho WH, Song WS, et al.: Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res 2007; 463: 157-165.
14. Rosen G, Marcove RC, Huvos AG, et al.: Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106: 55-67.
15. Gobel V, Jurgens H, Etspuler G, et al.: Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987; 113: 187-191.
16. Brismar J:, Understanding receiver-operating-characteristic curves: A graphic approach. AJR Am J Roentgenol 1991; 157: 1119-1121.
17. Lewis IJ, Nooij MA, Whelan J, et al.: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
18. Salzer-Kuntschik M, Brand G, Delling G:, Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 1983; 4: 135-141.
19. Picci P, Bacci G, Campanacci M, et al.: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985; 56: 1515-1521.
20. Kim MS, Lee SY, Cho WH, et al.: Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 2008; 15: 906-914.
21. Jones KB, Ferguson PC, Lam B, et al.: Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. J Bone Joint Surg Am 2012; 94: 1399-1405.
22. Meyers PA, Heller G, Healey J, et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
23. Provisor AJ, Ettinger LJ, Nachman JB, et al.: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
24. Wittig JC, Bickels J, Kellar-Graney KL, et al.: Osteosarcoma of the proximal humerus: Long-term results with limb-sparing surgery. Clin Orthop Relat Res 2002; 397: 156-176.
25. Cho WH, Song WS, Jeon DG, et al.: Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann Surg Oncol 2010; 17: 702-708.
26. Kim MS, Lee SY, Cho WH, et al.: An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J Surg Oncol 2008; 98: 427-431.
27. Manoso MW, Healey JH, Boland PJ, et al.: De novo osteogenic sarcoma in patients older than forty: Benefit of multimodality therapy. Clin Orthop Relat Res 2005; 438: 110-115.
28. Grimer RJ, Cannon SR, Taminiau AM, et al.: Osteosarcoma over the age of forty. Eur J Cancer 2003; 39: 157-163.